Pluristem Therapeutics (PSTI) is a developer of placenta-based cell therapies. They have just formed a strategic alliance with Cha Bio&Diostech. Furthermore, they filed their first Investigational New Drug Application (IND) for their product known as Pluristem’s PLacental eXpanded cells with the Korean Food and Drug Administration.
The PLX will be used for the treatment of intermittent claudication as well as peripheral arterial diseases (PAD). Their approach parallels the protocol used by Pluritsem in their USA trials. With the alliance with Cha, Pluristem will have access to a lot more capital as well as resources to conduct more trials in Korea and to fulfill unmet medical needs on a more global basis. Market Cap: 180.02 million; Volume: 600; 12 Month Trail: $2.45-$5.00.
Through our news, radio interviews, video production, and research, OneMedPlace specializes in delivering information to investors covering nanocap, microcap and private emerging growth companies in the hottest areas of life sciences. OneMedPlace covers what we believe to be an undervalued sector, and has built a network of investors at all levels of financial and strategic development. OneMedPlace produces two investor conferences, OneMedForumSF in January and OneMedForumNY in June, bringing together our diverse network to meet the most promising companies in life sciences. Visit our website to learn more about attending.